

PD-L1 Testing Algorithm


[Click here for topics associated with this algorithm](#)

Abbreviations

ESCC	Esophageal squamous cell carcinoma
GEJ	Gastroesophageal junction
HNSCC	Head and neck squamous cell carcinoma
NSCLC	Non-small cell lung cancer
MMR	Mismatch repair
MSI	Microsatellite instability
TNBC	Triple-negative breast cancer

INDICATIONS FOR TESTING
 Predict response to PD-L1 inhibitors in patients with varied malignancies

PD-L1 inhibitor therapy



^aMSI/MMR-deficient tumors: KEYTRUDA has been approved for these tumors, irrespective of site. No PD-L1 testing is required. Testing to establish MSI/MMR-deficient status is required.
^bMSI/MMR-deficient colorectal carcinomas: OPDIVO has been approved for these cancers. No PD-L1 testing is required. Testing to establish MSI/MMR-deficient status is required.
 Note: PD-L1 SP142 for treatment with atezolizumab (TECENTRIQ) and PD-L1 SP263 for treatment with durvalumab (IMFINZI) tests are also available for ordering at some laboratories.